The Pediatric infectious disease journal · 2025
Cefiderocol in Combination With Trimethoprim-sulfamethoxazole for Multidrug-resistant Stenotrophomonas maltophilia Ventilator-associated Pneumonia in an Extremely Preterm Infant: A Case Report.
СтатьяКлинический случайНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pesce Simona, Scavone Maria, Guarini Giuseppe, Gilio Michele, Stolfi Luisiana
Аннотация
BACKGROUND: Multidrug-resistant Stenotrophomonas maltophilia (MDR Sm) is an emerging neonatal pathogen with limited therapeutic options. Cefiderocol shows potent in vitro activity, but neonatal clinical data are scarce.
CASE PRESENTATION: We report an extremely preterm male infant (27 + 2 weeks, 800 g) who developed ventilator-associated pneumonia due to a metallo-β-lactamase-producing MDR Sm on day 50 of life.
MANAGEMENT AND OUTCOMES: Targeted therapy with cefiderocol (100 mg/kg q8h) plus trimethoprim-sulfamethoxazole (7 mg/kg q8h) led to extubation within 24 hours, C-reactive protein normalization within 72 hours, and radiographic clearance by day 14. No adverse events occurred. The infant was discharged on room air and remained well at 6-month follow-up.
CONCLUSIONS: Cefiderocol may represent a safe and effective salvage option for MDR Sm ventilator-associated pneumonia in extremely preterm neonates, but further pharmacokinetic, pharmacodynamic and stewardship studies are needed.
CASE PRESENTATION: We report an extremely preterm male infant (27 + 2 weeks, 800 g) who developed ventilator-associated pneumonia due to a metallo-β-lactamase-producing MDR Sm on day 50 of life.
MANAGEMENT AND OUTCOMES: Targeted therapy with cefiderocol (100 mg/kg q8h) plus trimethoprim-sulfamethoxazole (7 mg/kg q8h) led to extubation within 24 hours, C-reactive protein normalization within 72 hours, and radiographic clearance by day 14. No adverse events occurred. The infant was discharged on room air and remained well at 6-month follow-up.
CONCLUSIONS: Cefiderocol may represent a safe and effective salvage option for MDR Sm ventilator-associated pneumonia in extremely preterm neonates, but further pharmacokinetic, pharmacodynamic and stewardship studies are needed.
Предметные рубрики MeSH
HumansPneumonia, Ventilator-AssociatedStenotrophomonas maltophiliaMaleAnti-Bacterial AgentsGram-Negative Bacterial InfectionsCephalosporinsInfant, NewbornDrug Resistance, Multiple, BacterialTrimethoprim, Sulfamethoxazole Drug CombinationInfant, Extremely PrematureCefiderocolDrug Therapy, CombinationTreatment Outcome